Gilead Sciences, Inc. (GILD) Stock Score, Valuation & Financial Research
Gilead Sciences, Inc. is in the Healthcare sector and Drug Manufacturers - General industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 29/100.
Quick answer for GILD
Gilead Sciences, Inc. currently has a Wall Street Score of 29/100. The stored market price is $143.72. Its financial score is 34/100. Its valuation score is 16/100. The latest WSS change is -9.7 points. These figures are a research snapshot, not a buy or sell recommendation.
What Gilead Sciences, Inc. does
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy
GILD financial snapshot
- Wall Street Score:
- 29/100
- Current price:
- $143.72
- Market capitalization:
- $178.44B
- Revenue:
- $30.46B
- Net income:
- $-3.24B
- Free cash flow:
- $9.46B
- Cash:
- $3.18B
- Total debt:
- $26.25B
- EPS:
- 6.84
- P/E ratio:
- 21.0x
- Financial score:
- 34/100
- Valuation score:
- 16/100
- Revenue score:
- 9/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $9.46B, showing positive cash generation.
- The balance sheet shows $3.18B of cash versus $26.25B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -9.7 points: GILD decreased 9.7 points because Revenue declined by 15.7 points, Asset declined by 2.4 points, Capital declined by 31 points.
What the numbers mean
Its current valuation score is 16/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 34/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research GILD
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.